<DOC>
	<DOCNO>NCT02421289</DOCNO>
	<brief_summary>Genetic polymorphism cytochrome P450 2B6 ( CYP2B6 ) associate low rate EFV metabolism lead high exposure , well high risk neuropsychiatric adverse event especially homozygous variant CYP2B6 *6/*6 . This trial design compare proportion patient undetectable HIV RNA 24 week ART initiation patient CYP 2B6 guide EFV dose .</brief_summary>
	<brief_title>Influence Cytochrome P2B6 Efavirenz Dose HIV-infected Thai Patients</brief_title>
	<detailed_description />
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Age ≥18 year old AntiHIV positive Naïve antiretroviral drug Meet criterion start ART Thai National guideline Sign inform consent Body mass index ( BMI ) &gt; 25 kg/m² Pregnant woman breastfeed Received drug may interaction EFV e.g . rifampicin , fluconazole ( 400800 mg ) , ergot alkaloid , midazolam , triazolam , ritonavir , carbamazepine , phenytoin , phenobarbitone , St John 's Wort Having active opportunistic infection e.g . tuberculosis , cryptococcosis , histoplasmosis , penicillosis Hepatic dysfunction indicate : Transaminases &gt; 510 × upper limit normal ALP &gt; 510 × upper limit normal Total bilirubin &gt; 2.55 × upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>CYP2B6 polymorphism</keyword>
	<keyword>efavirenz</keyword>
	<keyword>Thai</keyword>
	<keyword>HIV-infected patient</keyword>
	<keyword>pharmacogenomic</keyword>
</DOC>